Indefinite Delivery Contract 75D30123D16112
Award Date
4/1/23
Last Date to Order
3/31/24
Federal Agency
CDC Pittsburgh
Awardee
Grifols USA LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention (CDC) awarded an Indefinite Delivery Contract (IDC) worth up to $13,017,750 to Grifols USA LLC for the provision of various pediatric vaccines. The contract has an ultimate completion date of March 31, 2023 and was awarded on April 1, 2022 without any set-aside designations, indicating Grifols' capability as a large business to fulfill substantial federal vaccine requirements. The IDC supports the CDC's Vaccines for Children program and other...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Grifols USA LLC, a global healthcare company and manufacturer of essential plasma-derived medicines and vaccines. The contract, valued at a ceiling of $12,409,500, is for the supply of 20 standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the...
The Centers for Disease Control and Prevention awarded an indefinite delivery contract to Grifols USA LLC to supply 20 standard pediatric vaccines in support of the Vaccines for Children program. The contract utilizes multiple awards with a potential value of $12.2 million and period of performance through March 2022. Vaccines will be ordered via task orders against flexible delivery schedules to meet quantities ranging from a minimum of 100 doses to a maximum of 13 million doses per item. The...
The Centers for Disease Control and Prevention awarded Grifols USA LLC an indefinite delivery contract for 2019 adult vaccines. The multiple award IDC has a potential value of $1,602,700 and a period of performance from July 1, 2019 through June 30, 2020. Grifols will supply various adult vaccines to support public health programs through the CDC. As a manufacturer of pharmaceuticals and medical products, Grifols has extensive experience providing specialized drugs, vaccines, immunoglobulins and...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company, to provide a wide range of pediatric vaccines over a period of performance from April 1, 2024 to March 31, 2025. The contract has a ceiling value of $1,334,738,300 and is part of the CDC's National Center for Immunization and Respiratory Diseases (NCIRD) effort to support pediatric immunization programs under...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency, to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The contract, valued at up to $1.489 billion, is for the procurement of standard commercial pediatric vaccines to support the Vaccines for Children (VFC) program over a 12-month period from April 1, 2025 to March 31, 2026. The solicitation was unrestricted, without any small business...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide a range of pediatric vaccines for the Vaccines for Children (VFC) program. The $1.26 billion, multiple-award IDC has a period of performance from April 1, 2023 through March 31, 2024. The contract aims to procure a minimum of 100 doses up to a maximum ranging from 100,000 to 13 million doses of 21 different pediatric vaccines,...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide up to 23 standard pediatric vaccines. The $1.14 billion, multiple-award contract has a period of performance from April 1, 2022 to March 31, 2023 and supports pediatric immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program. The vaccines, which must have a minimum...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to provide a range of standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. The $1.6 billion multiple-award IDC has a period of performance from April 1, 2021 through March 31, 2022, with no small business set-asides utilized. The...
This federal contract indefinite delivery vehicle (IDV) was awarded to Grifols USA LLC by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to provide a variety of adult vaccines. The contract has a potential value of $1,647,100 and a period of performance from July 1, 2021 to June 30, 2022. The vaccines to be supplied under this IDV include hepatitis, pneumococcal, tetanus/diphtheria, herpes zoster, measles/mumps/rubella, meningococcal, human...